Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105270 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL4105264 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL7990788 | 0.94 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL7990793 | 0.94 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL7990784 | 0.94 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL7976808 | 0.90 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL7976799 | 0.90 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL7976804 | 0.90 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL7976569 | 0.90 | LTB4R (0.82) | LTB4RLTB4R2 | |
| SCHEMBL7976565 | 0.90 | LTB4R (0.82) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | LTB4R 1/4885LTB4R2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.